When we stratified patients by the presence of MSI-H and/or a RAS/BRAF mutation, consistent with current American Society of Clinical Oncology and European Society for Medical Oncology guidelines2,25, patients appeared more appropriately selected for anti-EGFR therapy than when stratified by tumor sidedness alone. This evidence concerns the gene EGFR and neoplasm.